US7597915B2 - Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne - Google Patents

Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne Download PDF

Info

Publication number
US7597915B2
US7597915B2 US10/579,966 US57996604A US7597915B2 US 7597915 B2 US7597915 B2 US 7597915B2 US 57996604 A US57996604 A US 57996604A US 7597915 B2 US7597915 B2 US 7597915B2
Authority
US
United States
Prior art keywords
composition
extract
content
terpenes
floroglucinols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US10/579,966
Other versions
US20070071839A1 (en
Inventor
Ezio Bombardelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Assigned to INDENA S.P.A. reassignment INDENA S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOMBARDELLI, EZIO
Publication of US20070071839A1 publication Critical patent/US20070071839A1/en
Application granted granted Critical
Publication of US7597915B2 publication Critical patent/US7597915B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/758—Zanthoxylum, e.g. pricklyash
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to compositions containing medicinal plant extracts or purified or standardized fractions thereof, useful in the treatment of atopic dermatitis, skin allergic conditions and acne.
  • Atopic dermatites are characterized by persistent inflammatory conditions which may cause lacerations of the skin with possible infections. Inflammation is often accompanied by intense itching; the consequent scratching by the patient may further irritate the affected area.
  • Dermatites which are also frequently referred to as eczema, are superficial skin inflammations, with acute or chronic course and variable clinical and histological manifestations, which affect an unnegligible percentage of population (2-3%).
  • the etiology of the various forms of dermatitis is still partly unclear, although the immune component is definitely one of the factors.
  • the pathological manifestations are often alike, and are mainly characterized by the presence of papules, erythematous spots and vesicles, which can form plaques, edema, scaling-crusting lesions and the like.
  • the most common dermatites comprise atopic dermatitis, contact allergies, contact dermatitis, stasis dermatitis, seborrheic dermatitis, lichen simplex and acne vulgaris.
  • the choice treatment consists in the use of corticosteroids, which involve well-known side effects (possible secondary infections, inefficacy after prolonged use, and the like).
  • compositions of the invention comprise:
  • the Ginkgo biloba content can range from 0.1 to 2%; the floroglucinols content can range from 0.1 to 1%; and the Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract content can range from 0.01 to 0.5%.
  • Ginkgo biloba terpenes are present in the free form or preferably in the form of complex with natural or synthetic phospholipids.
  • Ginkgo biloba terpenes herein means the terpenes, either pure or in a mixture wherein the total triterpenes content ranges from 60 to 100%, preferably 90%, the bilobalide content ranges from 20 to 70%, preferably 45%, and ginkgolides A, B, C and J total content ranges from 25 to 75%, preferably 50%.
  • Ginkgo biloba terpenes in addition to the antinflammatory action, also exert antiallergic action, as observed in a number of models both in animals and humans, thereby reducing one of the symptoms involved, which keep irritation and the continuous recidivation.
  • This antiallergic action makes said terpenes particularly useful when an immune factor is involved in the etiology.
  • Floroglucinols either pure or in a mixture thereof extracted from Humulus lupulus, Hypericum sp and Mirtus sp., are active against anaerobic bacteria such as Propionibacterium acnis and the like and on Candida albicans strains, at concentrations of 0.5-4 ⁇ g/mL.
  • Humulus lupulus extracts are characterized by a floroglucinols content of 20 to 80%, preferably 60%.
  • a Hypericum perforatum extract with a floroglucinols (adhyperforin/hyperforin) content ranging from 20 to 80%, preferably 60%.
  • an extract of Mirtus communis leaves prepared by extraction with carbon dioxide under pressure ranging from 235 to 260 bars, at a temperature ranging from 40 to 60° C., preferably a 45° C. The resulting extract usually contains about 35% of mirtocumulone.
  • compositions of the invention containing a Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract enriched in isobutylamides, active as topical analgesics inhibiting the nervous conduction proved particularly effective in the treatment of localized itching. Therefore, according to a preferred aspect, the compositions of the present invention will contain, as component c), a Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract enriched in isobutylamides.
  • the Zanthoxylum extract can be prepared for example as disclosed in WO 00/02570, while the Echinacea extract can be prepared for example as disclosed in EP 0 464 298.
  • compositions of the invention further containing natural compounds with estrogenic and/or antiandrogenic action proved particularly effective in the treatment of seborrheic dermatitis and acne. Therefore, according to a preferred aspect, the compositions of the present invention will contain, in addition to components a), b) and c) above, also natural compounds with estrogenic action, such as ferutinine and/or extracts of various Ferula species, and/or natural compounds with antiandrogenic action, such as lauric acid.
  • natural compounds with estrogenic action such as ferutinine and/or extracts of various Ferula species
  • antiandrogenic action such as lauric acid.
  • compositions of the present invention will contain Oenothera biennis oil as lipophilic excipient.
  • compositions for the treatment of atopic dermatitis, skin allergic conditions and acne containing the combinations described above.
  • Said compositions will be prepared according to conventional methods well known in the pharmaceutical technique, such as those described in “Remington's Pharmaceutical Handbook”, Mack Publishing Co., N.Y., USA, together with suitable excipients commonly used in the art.

Abstract

The present invention relates to topical compositions containing: a) Ginkgo biloba terpenes; b) floroglucinols pure or in mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp; c) Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract; for the treatment of atopic dermatitis, skin allergic conditions and acne.

Description

The present invention relates to compositions containing medicinal plant extracts or purified or standardized fractions thereof, useful in the treatment of atopic dermatitis, skin allergic conditions and acne.
PRIOR ART
Atopic dermatites are characterized by persistent inflammatory conditions which may cause lacerations of the skin with possible infections. Inflammation is often accompanied by intense itching; the consequent scratching by the patient may further irritate the affected area.
Dermatites, which are also frequently referred to as eczema, are superficial skin inflammations, with acute or chronic course and variable clinical and histological manifestations, which affect an unnegligible percentage of population (2-3%).
The etiology of the various forms of dermatitis is still partly unclear, although the immune component is definitely one of the factors. The pathological manifestations are often alike, and are mainly characterized by the presence of papules, erythematous spots and vesicles, which can form plaques, edema, scaling-crusting lesions and the like. The most common dermatites comprise atopic dermatitis, contact allergies, contact dermatitis, stasis dermatitis, seborrheic dermatitis, lichen simplex and acne vulgaris.
The choice treatment consists in the use of corticosteroids, which involve well-known side effects (possible secondary infections, inefficacy after prolonged use, and the like).
DISCLOSURE OF THE INVENTION
It has now been found that compositions containing:
    • a) an extract, fraction thereof or pure compound with inflammatory action;
    • b) an extract, fraction thereof or pure compound, with antimicrobial and/or antifungal action; and
    • c) an extract, fraction thereof or pure compound, with anti-itching action;
exert immediate, beneficial effect to the patient and induce the fast remission of the pathological condition, even compared with known medicaments such as topical anti-inflammatories and steroids.
More precisely, the compositions of the invention comprise:
    • a) Ginkgo biloba terpenes;
    • b) floroglucinols, either pure or in mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp;
    • c) Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract.
According to the present invention, the Ginkgo biloba content can range from 0.1 to 2%; the floroglucinols content can range from 0.1 to 1%; and the Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract content can range from 0.01 to 0.5%.
According to the invention, Ginkgo biloba terpenes are present in the free form or preferably in the form of complex with natural or synthetic phospholipids. “Ginkgo biloba terpenes” herein means the terpenes, either pure or in a mixture wherein the total triterpenes content ranges from 60 to 100%, preferably 90%, the bilobalide content ranges from 20 to 70%, preferably 45%, and ginkgolides A, B, C and J total content ranges from 25 to 75%, preferably 50%.
Ginkgo biloba terpenes, in addition to the antinflammatory action, also exert antiallergic action, as observed in a number of models both in animals and humans, thereby reducing one of the symptoms involved, which keep irritation and the continuous recidivation. This antiallergic action makes said terpenes particularly useful when an immune factor is involved in the etiology.
Floroglucinols, either pure or in a mixture thereof extracted from Humulus lupulus, Hypericum sp and Mirtus sp., are active against anaerobic bacteria such as Propionibacterium acnis and the like and on Candida albicans strains, at concentrations of 0.5-4 μg/mL.
In particular, Humulus lupulus extracts are characterized by a floroglucinols content of 20 to 80%, preferably 60%. Among the extracts of Hypericum sp., particularly preferred is a Hypericum perforatum extract with a floroglucinols (adhyperforin/hyperforin) content ranging from 20 to 80%, preferably 60%. Among the extracts of Mirtus sp, particularly preferred is an extract of Mirtus communis leaves prepared by extraction with carbon dioxide under pressure ranging from 235 to 260 bars, at a temperature ranging from 40 to 60° C., preferably a 45° C. The resulting extract usually contains about 35% of mirtocumulone.
The compositions of the invention containing a Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract enriched in isobutylamides, active as topical analgesics inhibiting the nervous conduction proved particularly effective in the treatment of localized itching. Therefore, according to a preferred aspect, the compositions of the present invention will contain, as component c), a Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract enriched in isobutylamides. The Zanthoxylum extract can be prepared for example as disclosed in WO 00/02570, while the Echinacea extract can be prepared for example as disclosed in EP 0 464 298.
The compositions of the invention further containing natural compounds with estrogenic and/or antiandrogenic action proved particularly effective in the treatment of seborrheic dermatitis and acne. Therefore, according to a preferred aspect, the compositions of the present invention will contain, in addition to components a), b) and c) above, also natural compounds with estrogenic action, such as ferutinine and/or extracts of various Ferula species, and/or natural compounds with antiandrogenic action, such as lauric acid.
According to a further preferred aspect, the compositions of the present invention will contain Oenothera biennis oil as lipophilic excipient.
The present invention, therefore, relates to topical compositions for the treatment of atopic dermatitis, skin allergic conditions and acne, containing the combinations described above. Said compositions will be prepared according to conventional methods well known in the pharmaceutical technique, such as those described in “Remington's Pharmaceutical Handbook”, Mack Publishing Co., N.Y., USA, together with suitable excipients commonly used in the art.
The examples reported hereinbelow further illustrate the invention.
EXAMPLE 1
Oil-in-water emulsion
Ginkgo biloba terpenes in form 0.5 g
of phospholipid complexes
Humulus lupulus extract 0.1 g
(60% in floroglucinols)
Zanthoxylum bungeanum extract 0.05 g 
Oenothera biennis oil 5.0 g
Polyoxyethylene glycol-20 glyceryl stearate 10.0 g 
C10-C18 triglycerides 10.0 g 
Glycerin 5.0 g
Hydroxylated lanolin 0.5 g
Hydroxyethyl cellulose 0.5 g
Methyl and propyl paraben 0.2 g
Tocopherol 0.1 g
Purified water q.s. to 100.0 g
EXAMPLE 2
Oil-in-water emulsion
Ginkgo biloba terpenes in form 0.5 g
of phospholipid complexes
Mirtus communis lipophilic extract 0.1 g
(35% in mirtocumulone)
Zanthoxylum bungeanum extract 0.05 g 
Oenothera biennis oil 5.0 g
Stearic acid 10.0 g 
Mineral oil 6.0 g
White petrolatum 6.0 g
Sorbitan monostearate 2.0 g
Polyoxyethylene sorbitan monostearate 1.0 g
Methyl and propyl paraben 0.2 g
Purified water q.s. to 100.0 g
EXAMPLE 3
Cream
Ginkgo biloba terpenes in form 0.5 g
of phospholipid complexes
Humulus lupulus extract 0.1 g
(60% in floroglucinols)
Echinacea angustifolia extract 0.05 g 
Oenothera biennis oil 5.0 g
Stearic acid 12.0 g 
Glycerin 10.0 g 
Cetostearyl alcohol 2.0 g
Potassium hydroxide 0.9 g
Methyl and propyl paraben 0.2 g
Purified water q.s. to 100.0 g
EXAMPLE 4
Cream
Ginkgo biloba terpenes in form 0.5 g
of phospholipid complexes
Hypericum perforatum extract 0.1 g
(60% in floroglucinols)
Echinacea angustifolia extract 0.05 g 
Oenothera biennis oil 5.0 g
Stearic acid 12.0 g 
Glycerin 10.0 g 
Cetostearyl alcohol 2.0 g
Potassium hydroxide 0.9 g
Methyl and propyl paraben 0.2 g
Purified water q.s. to 100.0 g
EXAMPLE 5
Cream
Ginkgo biloba terpenes in form 0.5 g
of phospholipid complexes
Humulus lupulus extract 0.1 g
(60% in floroglucinols)
Zanthoxylum bungeanum extract 0.05 g 
Oenothera biennis oil 5.0 g
Ferutinine 0.3 g
Lauric acid 0.3 g
Cetostearyl alcohol 20.0 g 
White petrolatum 15.0 g 
Propylene glycol 10.0 g 
Sodium lauryl sulfate 1.0 g
Methyl and propyl paraben 0.2 g
Purified water q.s. to 100.0 g

Claims (22)

1. A topical composition for the treatment of atopic dermatitis, skin allergic conditions or acne, comprising:
effective amounts of:
a) Ginkgo biloba terpenes, the terpenes being either pure or in a mixture having a total triterpenes content from 60 to 100%;
b) floroglucinols, either pure or in mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp; and
c) Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract.
2. The composition as claimed in claim 1, wherein the effective amounts are:
a) 0.1 to 2% Ginkgo biloba terpenes;
b) 0.1 to 1% floroglucinols, either pure or in a mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp; and
c) 0.01 to 0.5% of Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract.
3. The composition as claimed in claim 1, wherein Ginkgo biloba terpenes are present in free form.
4. The composition as claimed in claim 1, wherein Ginkgo biloba terpenes are present in the form of a complex with natural or synthetic phospholipids.
5. The composition as claimed in claim 4, wherein the total triterpenes content ranges from 60 to 100%.
6. The composition as claimed in claim 5, wherein the total triterpenes content is 90%.
7. The composition as claimed in claim 4, wherein the terpenes comprises bilobalides and wherein the bilobalide content ranges from 20 to 70%.
8. The composition as claimed in claim 7, wherein the bilobalide content is 45%.
9. The composition as claimed in claim 4, wherein the terpenes comprises ginkolides A, B, C, and J, and wherein the total A, B, C and J ginkgolides content ranges from 25 to 75%.
10. The composition as claimed in claim 9, wherein the total A, B, C and J ginkgolides content is 50%.
11. The composition as claimed in claim 1, wherein the floroglucinols content of the Humulus lupulus extract ranges from 20 to 80%.
12. The composition as claimed in claim 11, wherein the floroglucinols content of the Humulus lupulus extract is 60%.
13. The composition as claimed in claim 1, wherein the Hypericum sp. extract is a Hypericum perforatum extract in which the floroglucinols content ranges from 20 to 80%.
14. The composition as claimed in claim 13, wherein the floroglucinols content of the Hypericum perforatum extract is 60%.
15. The composition as claimed in claim 1, wherein the extract of Mirtus sp is communis leaves and is prepared by extraction with carbon dioxide under conditions of pressure ranging from 235 to 260 bars and temperatures ranging from 40 to 60° C.
16. The composition as claimed in claim 15, wherein the Mirtus sp. extract is an extract of Mirtus communis leaves with a mirtocumulone content of 35%.
17. The composition as claimed in claim 1, wherein the Zanthoxylum gungeanum or Echinacea angustifolia lipophilic extract is enriched in isobutylamides.
18. The composition as claimed in claim 1, further comprising ferutinine.
19. The composition as claimed in claim 1, further comprising extracts of various Ferula species.
20. The composition as claimed in claim 1, further comprising lauric acid.
21. The composition as claimed in claim 1, further comprising Oenothera biennis oil as a lipophilic excipient.
22. A Method for the treatment of atopic dermatitis, skin allergic conditions or acne, which comprises administering to a patient in need thereof an effective amount of a medicament comprising:
a) Ginkgo biloba terpenes, the terpenes being either pure or in a mixture having a total triterpenes content from 60 to 100%;
b) floroglucinols pure or in a mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp; and
c) Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract.
US10/579,966 2003-11-24 2004-11-08 Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne Active US7597915B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002286A ITMI20032286A1 (en) 2003-11-24 2003-11-24 COMPOSITIONS FOR THE TREATMENT OF ATOPIC DERMATITES OF SKIN ALLERGIC AND ACNE STATES
ITMI2003A002286 2003-11-24
PCT/EP2004/012608 WO2005053720A1 (en) 2003-11-24 2004-11-08 Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne

Publications (2)

Publication Number Publication Date
US20070071839A1 US20070071839A1 (en) 2007-03-29
US7597915B2 true US7597915B2 (en) 2009-10-06

Family

ID=34640360

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/579,966 Active US7597915B2 (en) 2003-11-24 2004-11-08 Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne

Country Status (21)

Country Link
US (1) US7597915B2 (en)
EP (1) EP1713490B1 (en)
JP (1) JP2007512271A (en)
KR (1) KR20060097127A (en)
CN (1) CN1886146A (en)
AT (1) ATE359803T1 (en)
AU (1) AU2004294691B2 (en)
BR (1) BRPI0416846B1 (en)
CA (1) CA2546959C (en)
CY (1) CY1111003T1 (en)
DE (1) DE602004006027T2 (en)
DK (1) DK1713490T3 (en)
ES (1) ES2286694T3 (en)
IL (1) IL175846A (en)
IT (1) ITMI20032286A1 (en)
NO (1) NO337517B1 (en)
PL (1) PL1713490T3 (en)
PT (1) PT1713490E (en)
RU (1) RU2361601C2 (en)
SI (1) SI1713490T1 (en)
WO (1) WO2005053720A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946413A (en) * 2004-04-29 2007-04-11 格泰克有限公司 Ginkgo leaf extract and its preparation method
US7491414B2 (en) * 2005-10-12 2009-02-17 Gaia Herbs, Inc. Anti-inflammatory substances extracted from Echinacea
JP2008031095A (en) * 2006-07-28 2008-02-14 Kao Corp Scf binding inhibitor
FR2905854B1 (en) * 2006-09-15 2010-07-30 Fabre Pierre Dermo Cosmetique COMPOSITION BASED ON XANTHOXYLINE AND ITS USE IN COSMETICS
US7642062B2 (en) * 2006-12-29 2010-01-05 Avon Products Inc. Compositions and methods of their use for improving the condition and appearance of skin
KR100834697B1 (en) * 2007-01-08 2008-06-02 주식회사 엘지생활건강 Cosmetics or pharmaceutical composition containing extract of zanthoxylum bungeanum maxim, hyoscyamus niger l. or luffa cylindrica (l.) roem
ITMI20071136A1 (en) * 2007-06-04 2008-12-05 Velleja Res Srl TOPIC FORMULATIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY AND / OR INFECTIOUS STATES OF THE GENITAL AREA
GB2455585B (en) * 2008-01-16 2010-07-28 Ali Reza Rezai-Fard Capsicum seeds for the treatment of eczema and dermatitis
ITMI20080395A1 (en) * 2008-03-10 2009-09-11 Indena Spa FORMULATIONS FOR THE TREATMENT OF VARUCHE AND PSORIATIC PLATES
WO2011034591A1 (en) * 2009-09-17 2011-03-24 New York University Methods of blocking ultraviolet radiation and promoting skin growth using terpenes and terpenoids
JP2013530995A (en) * 2010-06-30 2013-08-01 ネステク ソシエテ アノニム Use of chicory acid and derivatives in dietary supplements to regulate skin pigmentation
IT1401141B1 (en) 2010-07-26 2013-07-12 Indena Spa FORMULATIONS CONTAINING EXTRACTS OF ECHINACEA ANGUSTIFOLIA AND ZINGIBER OFFICINALE USEFUL IN THE REDUCTION OF INFLAMMATION AND PERIPHERAL PAIN
ES2387973B1 (en) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. TOPICAL COMPOSITIONS CONTAINING DIAMINOOXIDASE FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH A LEVEL OF ELEVATED HISTAMINE THAT PERFORM A PAIN INCREASE.
WO2012170467A1 (en) 2011-06-07 2012-12-13 New York University Compositions and methods for restoring the stratum corneum and treating dermatological diseases
FR2992859B1 (en) * 2012-07-09 2014-10-03 Fabre Pierre Dermo Cosmetique USE OF COCETH ZINC SULFATE AS ANTIBACTERIAL AGENT AFTER PROPIONIBACTERIUM ACNES
KR101636817B1 (en) * 2014-03-28 2016-07-07 (주)보광코리아 Pharmaceutical composition for prophylaxis and treatment of acne, skin external preparation, and method for producing extract of physostegia virginiana
CN103961482A (en) * 2014-04-23 2014-08-06 湖州康企药业有限公司 Natural medicine for treating cutitis
PL412214A1 (en) * 2015-05-04 2016-11-07 Biovico Spółka Z Ograniczoną Odpowiedzialnością Composition of plants with anti-inflammatory, antiallergic and/or antiasthmatic properties and its applications
JP2017002029A (en) * 2015-06-11 2017-01-05 御木本製薬株式会社 Ctip2 GENE-EXPRESSION ENHANCER
EP3135341B1 (en) 2015-08-27 2019-02-20 Latvijas Universitate Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum
RU2666220C1 (en) * 2017-12-18 2018-09-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Medical and cosmetic means for patients with atopic dermatitis
RU2666222C1 (en) * 2017-12-20 2018-09-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Means for treatment of atopic dermatitis
RU2681944C1 (en) * 2018-04-24 2019-03-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Means for treating thermal burns
RU2681850C1 (en) * 2018-05-03 2019-03-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Means stimulating reparation of tissues with thermal burns
WO2023156066A1 (en) * 2022-02-17 2023-08-24 The Boots Company Plc Antioxidant compositions
WO2024052756A1 (en) * 2022-09-09 2024-03-14 Crodarom Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use.
FR3139467A1 (en) * 2022-09-09 2024-03-15 Crodarom Use of a Sichuan pepper extract for skin treatment and a composition adapted to this use.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108642B1 (en) * 1991-06-06 1994-07-29 Sc Miraj Sa Day cream for oily skin
US5578312A (en) * 1993-05-05 1996-11-26 Parrinello; Vincene M. Skin care system and method for improving moisture retention in skin
JPH1053532A (en) 1996-08-08 1998-02-24 Ichimaru Pharcos Co Ltd Antiallergic drug containing plant extract
EP0870507A1 (en) 1997-04-02 1998-10-14 Farmo-Nat Ltd. Synergistic herbal extracts
US6419950B2 (en) * 1998-07-07 2002-07-16 Indena Spa Extracts of zanthoxylum bungeanum, and pharmaceutical and cosmetic formulations containing same
US20040185123A1 (en) 2003-03-21 2004-09-23 Mazzio Elizabeth A. Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7008627B1 (en) * 1996-10-22 2006-03-07 Johnson & Johnson Consumer France Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions
US20060275246A1 (en) * 2003-04-04 2006-12-07 Indena S. P. A. Process for the preparation of ferutinine from ferula genus plants
US7166310B2 (en) * 2000-12-22 2007-01-23 Dr. Willmar Schwabe Gmbh & Co. Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108642B1 (en) * 1991-06-06 1994-07-29 Sc Miraj Sa Day cream for oily skin
US5578312A (en) * 1993-05-05 1996-11-26 Parrinello; Vincene M. Skin care system and method for improving moisture retention in skin
JPH1053532A (en) 1996-08-08 1998-02-24 Ichimaru Pharcos Co Ltd Antiallergic drug containing plant extract
US7008627B1 (en) * 1996-10-22 2006-03-07 Johnson & Johnson Consumer France Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions
EP0870507A1 (en) 1997-04-02 1998-10-14 Farmo-Nat Ltd. Synergistic herbal extracts
US6419950B2 (en) * 1998-07-07 2002-07-16 Indena Spa Extracts of zanthoxylum bungeanum, and pharmaceutical and cosmetic formulations containing same
US7166310B2 (en) * 2000-12-22 2007-01-23 Dr. Willmar Schwabe Gmbh & Co. Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament
US20040185123A1 (en) 2003-03-21 2004-09-23 Mazzio Elizabeth A. Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US20060275246A1 (en) * 2003-04-04 2006-12-07 Indena S. P. A. Process for the preparation of ferutinine from ferula genus plants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Fugh-Berman A A:, "Herb-drug interactions", Lancet, XX, XX, vol. 355, No. 9198, Jan. 8, 2000, pp. 134-138, XP004262991, ISSN: 0140-6736, the whole document.
Kiken David A et al:, "Contact dermatitis to botanical extracts.", American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, Sep. 2002, vol. 13, No. 3, Sep. 2002, pp. 148-152, XP009044006 ISSN: 1046-199X, the whole document.
More D R et al:, "Herbal supplements and skin testing: The lack of effect of commonly used herbal suulemnts on histamine skin prck testing.", Allergy (Copenhagen), vol. 58, No. 6, Jun. 2003, pp. 492-494, XP009044026 ISSN: 0105-4538 the whole document.
Patent Abstracts of Japan, vol. 1998, No. 06, Apr. 30, 1998, & JP 10 053532 A (Ichimaru Pharcos Co Ltd), Feb. 24, 1998 abstract.
Tamemoto et al, Sesquiterpenoids from the fruits of Ferula Kuhistanica and antibacterial activity of the consittuents of F. kuhistanica, Phytochemistry, vol. 5, Nov. 2001, pp. 763-767. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders

Also Published As

Publication number Publication date
EP1713490A1 (en) 2006-10-25
NO337517B1 (en) 2016-05-02
ATE359803T1 (en) 2007-05-15
CA2546959A1 (en) 2005-06-16
DE602004006027T2 (en) 2007-12-27
CY1111003T1 (en) 2015-06-11
IL175846A0 (en) 2006-10-05
RU2006117772A (en) 2007-12-10
EP1713490B1 (en) 2007-04-18
BRPI0416846B1 (en) 2015-01-13
KR20060097127A (en) 2006-09-13
JP2007512271A (en) 2007-05-17
IL175846A (en) 2009-12-24
NO20062354L (en) 2006-05-23
ITMI20032286A1 (en) 2005-05-25
CN1886146A (en) 2006-12-27
ES2286694T3 (en) 2007-12-01
PL1713490T3 (en) 2007-09-28
PT1713490E (en) 2007-07-24
WO2005053720A1 (en) 2005-06-16
AU2004294691A1 (en) 2005-06-16
AU2004294691B2 (en) 2010-07-08
DK1713490T3 (en) 2007-09-17
CA2546959C (en) 2014-07-15
SI1713490T1 (en) 2007-08-31
DE602004006027D1 (en) 2007-05-31
RU2361601C2 (en) 2009-07-20
US20070071839A1 (en) 2007-03-29
BRPI0416846A (en) 2007-02-13

Similar Documents

Publication Publication Date Title
US7597915B2 (en) Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne
DE60210752T2 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROTEOGLYKAN AND ITS USE IN THE TREATMENT OF INFLAMMATORY DISEASES
US20080114057A1 (en) Compositions and methods for the treatment of inflammatory conditions of the mucosae, skin and the eye
KR20150021126A (en) Andrographis paniculata extract
KR101239879B1 (en) Cosmetic composition for mitigating skin troubles
US7910139B2 (en) Compositions for the treatment of affections of the oral cavity and upper respiratory tract
EP0501205B1 (en) Antiphlogistic means
KR101861347B1 (en) Compositions for the treatment of peripheral ulcers of various origins
US20230055582A1 (en) Compositions and methods for treatment of inflammatory conditions and diseases of the skin
US20220280584A1 (en) Croton lechleri compositions for use in treating bleeding, wounds and infections
Gindi et al. Antiurolithiatic and invitro anti-oxidant activity of leaves of Ageratum conyzoides in rat
EP2229950B1 (en) Use of plants of the sideritis genus and extracts from same for treating attention deficit/hyperactivity disorder
US8337916B2 (en) Use of Aphanamixis polystacha extracts or fractions against 5-lipoxygenase mediated diseases
Akah et al. Eleusine indica Linn, Baertin (Poaceae) Ethanol Leaf Extract and Its Ethyl Acetate Fraction Display Potential Anti-inflammatory Activities
EP1226827B1 (en) Pharmaceutical composition comprising rutin and lespedeza capitata extract for treating oedema
JPS60181024A (en) Composition for dermatologic administration
Hochenegg Evaluation of the traditional and well-established use of Tormentillae rhizoma, Caryophylli flos and Caryophylli aetheroleum
Kanna et al. Pain Management in Oral Sub-Mucosal Fibrosis (OSMF) with Alternanthera sessilis (Matsyaakshi): An Adjuvant Therapy
KR20190111554A (en) Compositon for Prevention or Treatment of Allergic Skin Disease comprising Tribulus terrestris L
Anosike et al. Research Journal of Pharmaceutical, Biological and Chemical Sciences
US20130197054A1 (en) Composition Based on Vegetable Extract and Methods for the Treatment of Cutaneous Inflammatory Forms, in Particular Psoriasis

Legal Events

Date Code Title Description
AS Assignment

Owner name: INDENA S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOMBARDELLI, EZIO;REEL/FRAME:017924/0857

Effective date: 20060330

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12